missing translation for 'onlineSavingsMsg'
Learn More
Please login to your online account to display your discounted pricing

Promega RNasin™ Ribonuclease Inhibitor: Natural DFS Item

Ribonuclease inhibitors with broad-spectrum RNase inhibitory properties. Recombinant and native available. Plus version protects RNA before, during and after heating.

Manufacturer:  Promega N2115

 View more versions of this product

Catalog No. PR-N2115



  • Broad-Spectrum Inhibition of Common Eukaryotic RNases
  • Native, recombinant and oxidation-resistant forms available
  • Does not inhibit SP6, T7 or T3 RNA Polymerase; GoScript™ Reverse Transcriptase, AMV or M-MLV Reverse Transcriptase; or Taq DNA polymerase.
  • Use in many downstream assays: Inhibits a broad spectrum of eukaryotic RNases over a wide pH range (pH 5-8)
  • Maintains inhibitory activity over a wide temperature range

1 1U.S. Patents 4,966,964, 5,019,556, and 5,266,687; Australian Patents 616881 and 641261, are exclusively licensed to Promega Corporation.
2 U.S. Patent 5,552,302, Australian Patent 646803.



RT-PCR, protection of mRNA in cDNA synthesis reactions, in-vitro transcription/translation, Increase yield and activity of polysomes, improvement of in-vitro virus replication, improvement of RNA translation in homologous systems, performing RNase-free Antibody staining, enhancement of RNA yields from Riboprobe™ system RNA synthesis reactions
20 to 40U/μL
Amount of RNasin™ RNase inhibitor required to inhibit the activity of 5ng of RNase A by 50%, activity is measured by the inhibition of hydrolysis of Cytidine 2,3'-cyclic Monophosphate by RNase A